Bert Hoyt, Former Nike VP, Takes Strategic Role at dBio to Enhance Sports Tech Innovation

Bert Hoyt Takes Key Role at dBio

In a significant move for the sports and health technology sectors, Bert Hoyt, the former Vice President and General Manager at Nike, has been appointed as a board advisor at Decentralized Biotechnology Intelligence Holding Group Inc. (dBio). This strategic appointment is aimed at propelling the development of innovative technologies that seamlessly integrate athletic performance monitoring with real-time health data.

Hoyt brings over 32 years of extensive experience in the sports industry, having collaborated with some of the world’s most iconic brands and athletes. His expertise is expected to provide invaluable strategic insights to dBio as they pursue their mission to revolutionize personalized health and fitness technologies on a global scale.

Founded with a vision to enhance individuals' understanding of their own bodies, dBio is committed to utilizing data-driven feedback to optimize training, speed up recovery, and minimize the risk of injury. Central to dBio’s platform are proprietary technologies like gMOTCloud and StethoCloud.

Innovative Solutions for Athlete Wellness

gMOTCloud is especially revolutionary as it serves as a groundbreaking AI-powered kinesiology wearable, capturing intricate motion and gait metrics to maximize performance. On the other hand, StethoCloud, a lightweight portable stethoscope, offers continuous heart and breathing monitoring bolstered by AI-enhanced noise reduction. Together, these tools deliver cloud-based analytics and virtual coaching support, promoting safer and more effective training regimens.

With over 75 patents and a fully developed ecosystem combining AI modeling, hardware, software, and application development, dBio presents a comprehensive solution for optimizing performance and health management. Their offerings cater not only to elite athletes but also to fitness enthusiasts and have applications in telemedicine, rehabilitation, and elder care.

In pursuit of redefining the future of personalized health and performance technologies, dBio is fortified by strategic partnerships with leaders in medicine, science, and sports. Hoyt's insightful leadership is expected to drive significant growth and innovation in this dynamic landscape.

A Legacy of Leadership and Achievement

Bert Hoyt's journey in the sports industry began in 1989 with Puma, where he held various positions from product management to brand leadership. His tenure as General Manager of Puma International was pivotal, witnessing extraordinary growth for the brand between 1992 and 1998. In 1998, Hoyt transitioned to Nike, where for 22 years he served in various executive roles, culminating as VP and General Manager for Nike Western Europe and the EMEA region.

During his time at Nike, Hoyt's efforts were instrumental in transforming the brand's presence in markets including Germany, Global Football, and more broadly throughout Europe. He played a critical role in elevating Nike EMEA to market leadership, significantly increasing revenues from $3 billion to $7 billion in Western Europe alone, while the EMEA region achieved over $10 billion in revenue and maintained an EBIT of 24%.

Since leaving Nike in early 2021, Hoyt has also served as a non-executive director at JD Sports PLC, Crius Bidco Limited, Mast-Jaegermeister SE, and Cosnova GmbH, broadening his influence across industries beyond sports. Additionally, he is a former ATP tennis player, having competed professionally from 1977 to 1984.

Hoyt reflects on his decision to join dBio, stating, “Throughout my personal and professional life, I have been dedicated to helping athletes improve their performance and overall well-being. I believe that dBio’s innovations will open a new chapter in athlete capability, equipped with precise data that enhances both performance and wellness.”

In conclusion, Bert Hoyt's arrival at dBio signals a promising direction for the next generation of sports and health technologies. His experience and commitment to enhancing athletic performance will be a driving force behind dBio’s innovative solutions, shaping the future of health and wellness in sports.